NCT03858075 is a Phase 1 clinical trial of BLU-782 in Healthy Volunteers, sponsored by Blueprint Medicines Corporation.

Who is sponsoring NCT03858075?

NCT03858075 is sponsored by Blueprint Medicines Corporation.

What drugs are being tested in NCT03858075?

Interventions in NCT03858075: BLU-782, Placebo, BLU-782 taken with food.

What condition does NCT03858075 study?

NCT03858075 studies Healthy Volunteers.

Is NCT03858075 still recruiting?

NCT03858075 is currently completed. Last updated 8 November 2019.

Last reviewed 2019-11-08 · How we verify

NCT03858075

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

Completed Phase 1 Last updated 8 November 2019

What this trial tests

Phase 1 trial testing BLU-782 in Healthy Volunteers in 108 participants. Completed in 11 September 2019.

Timeline

12 February 2019

Primary endpoint
11 September 2019

11 September 2019

Quick facts

Lead sponsor	Blueprint Medicines Corporation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	basic science
Enrollment	108
Start date	12 February 2019
Primary completion	11 September 2019
Estimated completion	11 September 2019
Sites	1 location across United States

Drugs / interventions tested

BLU-782 — full drug profile →
Placebo
BLU-782 taken with food — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Blueprint Medicines Corporation — full company profile →

Who can join

Adults 19 to 65, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives of this study are to assess the safety, tolerability, pharmacokinetics (PK), and food effect of BLU-782 in healthy adult subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis.
Petersen MA, Tognatta R, Meyer-Franke A, Bushong EA, et al · · 2021 · cited 24× · PMID 34426831 · DOI 10.1093/brain/awab106
Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X, Wang H, Hao J. · · 2022 · cited 17× · PMID 35536530 · DOI 10.1007/s11010-022-04446-9
Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.
Zhou Y, Shi C, Sun H. · · 2025 · PMID 40274382 · DOI 10.1631/jzus.b2300779

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Blueprint Medicines Corporation trials

Trials by the same sponsor.

NCT07388511 — A Study of Elenestinib in Healthy Adult Female Participants · Phase 1 · recruiting
NCT07264959 — An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) · not yet recruiting
NCT07255638 — A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany · recruiting
NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations · recruiting
NCT06931405 — Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03858075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Blueprint Medicines Corporation
Last refreshed: 8 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03858075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing